PharmaCyte Biotech, Inc. (PMCB)Healthcare | Biotechnology | Las Vegas, United States | NasdaqCM
0.36 USD
0.00
(-1.205%) ⇩
(Oct. 13, 2026, 1:37 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 2:14 a.m. EDT
This biotech stock represents a classic value trap with no safety net. The company has suffered a brutal nine-year decline, losing over 98% of its value, with seven consecutive years of negative annual returns. Fundamentals are dire: the business is burning cash with negative operating cash flow, negative free cash flow, and a return on equity of nearly -44%. While the balance sheet shows a high current ratio, this is likely due to minimal liabilities rather than strong liquidity, and the negative earnings confirm the core business is not generating value. Management actions, such as buying shares and correcting option errors, are positive signs of integrity but cannot reverse the structural deterioration of the business model. The stock trades at a fraction of book value, but in biotech, a lack of revenue growth and persistent losses often mean the market is pricing in a total loss of capital. With no dividend to provide income and a statistical forecast showing very low reliability, there is no margin of safety here. The options flow confirms this desperation, with traders only willing to buy deep out-of-the-money calls hoping for a miracle, while hedging against a total wipeout. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.068617 |
| MSTL | 0.191980 |
| AutoETS | 0.201826 |
| AutoARIMA | 0.201829 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 28% |
| H-stat | 14.42 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 1.60 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 3,872,348 |
| Forward P/E | -0.95 |
| Beta | 0.68 |
| Website | https://pharmacyte.com |
As of Oct. 10, 2026, 2:14 a.m. EDT: Options activity reveals a distinct asymmetry in speculative positioning. Call volume is concentrated entirely in out-of-the-money strikes (specifically the $2.50 strike), indicating a 'lottery ticket' mentality where traders are betting on a massive, unlikely spike to double the stock price. Conversely, put volume is heavily skewed toward deep out-of-the-money strikes ($7.50) for longer-dated expirations, suggesting a hedge against a catastrophic collapse rather than a standard downside bet. The lack of interest in near-term, realistic price targets implies the market views the current range as a binary event zone rather than a trading range.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.645534 |
| Address1 | 3,960 Howard Hughes Parkway |
| Address2 | Suite 500 |
| All Time High | 961.0 |
| All Time Low | 0.3339 |
| Ask | 0.5114 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 125,620 |
| Average Daily Volume3 Month | 206,765 |
| Average Volume | 206,765 |
| Average Volume10Days | 125,620 |
| Beta | 0.68 |
| Bid | 0.28 |
| Bid Size | 2 |
| Book Value | 2.601 |
| City | Las Vegas |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.3607 |
| Current Ratio | 40.296 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 0.374 |
| Day Low | 0.35 |
| Display Name | PharmaCyte Biotech |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,755,288,000 |
| Earnings Timestamp Start | 1,754,942,400 |
| Ebitda Margins | 0.0 |
| Enterprise Value | -24,703,758 |
| Eps Forward | -0.38 |
| Eps Trailing Twelve Months | -2.31 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 917 595 2851 |
| Fifty Day Average | 0.480998 |
| Fifty Day Average Change | -0.120298 |
| Fifty Day Average Change Percent | -0.25010082 |
| Fifty Two Week Change Percent | -64.5534 |
| Fifty Two Week High | 1.51 |
| Fifty Two Week High Change | -1.1493 |
| Fifty Two Week High Change Percent | -0.7611258 |
| Fifty Two Week Low | 0.3339 |
| Fifty Two Week Low Change | 0.026800007 |
| Fifty Two Week Low Change Percent | 0.08026357 |
| Fifty Two Week Range | 0.3339 - 1.51 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,357,137,000,000 |
| Float Shares | 10,068,965 |
| Forward Eps | -0.38 |
| Forward P E | -0.9492106 |
| Free Cashflow | 2,566,726 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 2 |
| Fullday Change | -0.004399985 |
| Fullday Change Percent | -1.2051452 |
| Fullday Price | 0.3607 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.057439998 |
| Held Percent Institutions | 0.07105 |
| Implied Shares Outstanding | 10,735,649 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-08-10 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,777,507,200 |
| Last Split Date | 1,626,048,000 |
| Last Split Factor | 1:1550 |
| Long Business Summary | PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer. It also develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; license agreements with SG Austria Pte. Ltd.; and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada. |
| Long Name | PharmaCyte Biotech, Inc. |
| Market | us_market |
| Market Cap | 3,872,348 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_3563709 |
| Most Recent Quarter | 1,785,456,000 |
| Net Income To Common | -20,632,084 |
| Next Fiscal Year End | 1,809,043,200 |
| Non Diluted Market Cap | 4,600,225 |
| Open | 0.351 |
| Operating Cashflow | -3,939,827 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 917 595 2850 |
| Previous Close | 0.3651 |
| Price Hint | 4 |
| Price To Book | 0.13867743 |
| Profit Margins | 0.0 |
| Quick Ratio | 40.254 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.004399985 |
| Regular Market Change Percent | -1.2051452 |
| Regular Market Day High | 0.374 |
| Regular Market Day Low | 0.35 |
| Regular Market Day Range | 0.35 - 0.374 |
| Regular Market Open | 0.351 |
| Regular Market Previous Close | 0.3651 |
| Regular Market Price | 0.3607 |
| Regular Market Time | 1,791,913,063 |
| Regular Market Volume | 38,479 |
| Return On Assets | -0.083450004 |
| Return On Equity | -0.4399 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 10,735,649 |
| Shares Percent Shares Out | 0.0125 |
| Shares Short | 133,885 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 79,793 |
| Short Name | PharmaCyte Biotech, Inc. |
| Short Percent Of Float | 0.013200001 |
| Short Ratio | 0.35 |
| Source Interval | 15 |
| State | NV |
| Symbol | PMCB |
| Total Cash | 30,513,452 |
| Total Cash Per Share | 2.842 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.31 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 0.6767695 |
| Two Hundred Day Average Change | -0.31606948 |
| Two Hundred Day Average Change Percent | -0.4670268 |
| Type Disp | Equity |
| Volume | 38,479 |
| Website | https://pharmacyte.com |
| Zip | 89,169 |